Impact of solriamfetol treatment on sleep quality in Chinese patients with OSA-EDS: results of a randomized controlled trial
Abstract
Introduction Wake-promoting agents (WPAs), such as solriamfetol, have emerged as effective treatment options for treating excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA). However, the impact of solriamfetol on nocturnal sleep quality remains underexplored. This exploratory analysis of a 12-week, randomized, double-blind, placebo-controlled, multicenter, parallel-arm, phase 3 trial involving Chinese patients with OSA-EDS evaluated the effect of solriamfetol on nocturnal sleep quality. Methods Participants were randomized (1:1) to receive solriamfetol (150 mg) or placebo once daily. The coprimary efficacy endpoints were the changes from baseline to week 12 in mean sleep latency during the Maintenance Wakefulness Test and in Epworth Sleepiness Scale scores. The exploratory endpoints included changes in participants’ polysomnography (PSG) parameters from baseline at Weeks 2, 5, and 12. These parameters were unadjusted and hypothesis-generating. The sleep quality parameters included total sleep time (TST) and wakefulness after sleep onset (WASO). Respiratory parameters included mean oxygen saturation (SaO 2 ), minimum SaO 2 , apnea index, and apnea-hypopnea index (AHI). Results Of the 357 participants screened, 201 were included in the full analysis set (FAS) (solriamfetol, n = 101; placebo, n = 100). At all-time points (Weeks 2, 5, and 12), no significant changes in TST, WASO, stage N2 sleep, and AHI were observed between the solriamfetol and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 357 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.